Please assess the completion status of the following clinical trial:

Trial Title: Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 18 years old~* Congenital heart disease with pulmonary arterial hypertension and cyanosis (resting oxygen saturation \< 90% on room air)~* Stable on oral therapy (PDE5 inhibitor and/or endothelin blockade) for at least three months~Exclusion Criteria:~* Age \< 18 years old~* Current intravenous or subcutaneous prostacyclin therapy~* Resting Systemic Hypotension (Systolic blood pressure \< 85 mmHg)~* Women who are pregnant or may become pregnant (unwilling to utilize effective contraception), as well as nursing mothers~* Inability to ambulate~* Planned surgical procedure during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iloprost (Type: EXPERIMENTAL): Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).